12:00 AM
 | 
Oct 31, 2011
 |  BC Week In Review  |  Company News  |  Other News

Amsterdam Molecular neurology, hematology, endocrine/metabolic news

Amsterdam Molecular discontinued development of Glybera after CHMP's second recommendation against approval of the product in the EU for lipoprotein lipase (LPL) deficiency. The company will also reduce headcount by 50% to 45 and discontinue development of AMT-080, which was in preclinical testing for Duchenne muscular dystrophy (DMD). Amsterdam Molecular expects the changes to reduce its burn rate to €500,000-€600,000 ($694,000-$833,000) per month from...

Read the full 330 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >